Lisa DeschampsSVP, Chief Business Officer at Novartis Gene Therapies
Lisa is responsible for strategic planning and worldwide commercialization of pipeline and in-line assets across the extensive gene therapy portfolio within Novartis Gene Therapies (formerly AveXis). This includes managing significant revenue growth targets and profitability margins world-wide.
Prior to this role, Lisa was the Head of the Global Neuroscience Franchise. During her 25-year career at Novartis, Lisa has successfully brought highly specialized biologic and small molecule products from the clinic to commercialization in the areas of Cardiovascular, Respiratory, Rheumatology/Immunology and Neurology, including rare and Ultra-Rare disease areas. Throughout her tenure, Lisa has worked and led teams across U.S, Europe, LatCan and Asia/Pac in Strategic, Functional and General Management roles.
Lisa leads and serves on a number of executive teams across commercial and development within Novartis. She has garnered many industry awards and honors and has a number of philanthropic interests including domestic violence and pediatric cancer.
Lisa has an MBA in General Management from NYU Stern School of Business and a BBA in marketing from IONA College, Hagan School of Business